NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan · Delayed Price · Currency is TWD 19.00
-0.05 (-0.26%)
May 29, 2026, 1:11 PM CST
TPEX:4732 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -92.28 | 0.9 | 10.12 | 30.02 | 30.81 |
Depreciation & Amortization | 11.06 | 11.01 | 10.42 | 10.8 | 11.03 |
Other Amortization | - | - | - | 0.14 | 0.26 |
Loss (Gain) From Sale of Assets | - | - | - | -0 | - |
Loss (Gain) From Sale of Investments | - | - | -0.44 | -0.31 | 0.08 |
Stock-Based Compensation | 1.6 | 5.78 | 6.83 | 1.71 | - |
Provision & Write-off of Bad Debts | 0.01 | -0.02 | -0 | 0.04 | - |
Other Operating Activities | -23.07 | -4.92 | -4.47 | -1.42 | -0.16 |
Change in Accounts Receivable | -1.16 | 6.68 | -1.19 | 11 | -9.6 |
Change in Inventory | 4.91 | -1.87 | -22.94 | -3.76 | -18.09 |
Change in Accounts Payable | 2.35 | -7.47 | 13.57 | -10.56 | 16.37 |
Change in Unearned Revenue | -1.36 | 0.84 | 1.33 | -3.15 | -0.36 |
Change in Other Net Operating Assets | -13.79 | -13.73 | -2.05 | -20.65 | 3.57 |
Operating Cash Flow | -111.74 | -2.8 | 62.2 | 13.85 | 33.72 |
Operating Cash Flow Growth | - | - | 349.01% | -58.92% | -39.32% |
Capital Expenditures | -0.84 | -0.12 | -0.31 | - | - |
Sale of Property, Plant & Equipment | - | - | - | 0.01 | - |
Sale (Purchase) of Intangibles | -0.54 | -0.03 | -0.33 | -0.15 | -0.18 |
Investment in Securities | -77.93 | 67.93 | -18.31 | -52.39 | -32.65 |
Other Investing Activities | -0.71 | -0.84 | -0.78 | 0.6 | 0.78 |
Investing Cash Flow | -80.02 | 66.94 | -19.72 | -51.93 | -32.05 |
Long-Term Debt Repaid | -4.57 | -4.54 | -4.01 | -3.94 | -3.91 |
Net Debt Issued (Repaid) | -4.57 | -4.54 | -4.01 | -3.94 | -3.91 |
Issuance of Common Stock | 0.7 | 0.77 | - | - | - |
Repurchase of Common Stock | -26.44 | - | - | - | - |
Common Dividends Paid | - | -9.86 | -24.65 | -14.79 | -4.65 |
Other Financing Activities | - | 156.45 | - | - | - |
Financing Cash Flow | -30.32 | 142.83 | -28.66 | -18.73 | -8.56 |
Foreign Exchange Rate Adjustments | -0.2 | 0.42 | -0.25 | 0.22 | -0.12 |
Net Cash Flow | -222.27 | 207.4 | 13.58 | -56.59 | -7.01 |
Free Cash Flow | -112.58 | -2.91 | 61.9 | 13.85 | 33.72 |
Free Cash Flow Growth | - | - | 346.81% | -58.92% | -38.25% |
Free Cash Flow Margin | -63.69% | -1.30% | 38.65% | 6.06% | 13.50% |
Free Cash Flow Per Share | -2.31 | -0.06 | 1.24 | 0.28 | 0.68 |
Cash Interest Paid | - | 0.1 | 0.05 | 0.04 | 0.03 |
Cash Income Tax Paid | - | 0.41 | 4.24 | 1.3 | -0.02 |
Levered Free Cash Flow | -60.57 | 2.2 | 4.89 | 2.28 | 22.55 |
Unlevered Free Cash Flow | -60.52 | 2.26 | 4.92 | 2.3 | 22.57 |
Change in Working Capital | -9.05 | -15.54 | 39.75 | -27.12 | -8.29 |